The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Abstract
Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL(2)-C. Treatment of the dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity. Statins and fibrates are useful for treating elevated LDL in patients with and without diabetes or the metabolic syndrome. In addition, thiazolidinediones or niacin in combination with a statin show promise for correcting defects in LDL and HDL heterogeneity. The ultimate goal of treatment in this patient population is to prevent the development and progression of coronary artery disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mild hypertriglyceridemia, typically seen in treated type 2 diabetes, is probably related to the presence of central obesity and insulin resistance (83).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [83]
In the citing paper
“Unfortunately, hypertriglyceridemia is often not effectively treated, leading to a significant unmet therapeutic need in an increasingly obese population (Brunzell and Ayyobi, 2003).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Brunzell and Ayyobi, 2003
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Banting lecture 1988. Role of insulin resistance in human disease.
Reaven, G. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,801
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133
Flagged first, then by citations
1 of the 63 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Austin, 1988, Inheritance of low-density lipoprotein subclass patterns, Am J Hum Genet, 43, 838
- Greene, 2000, A Diabetes Outcome Progression Trial (ADOPT) of long-term rosiglitazone, metformin, and glyburide monotherapy in drug-naïve patients, Diabetes, 49, A343
- Home, 2002, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD), Diabetes, 51, A487
Cited by
Sorted by citations
Items 101–155 of 155
Ruderman, N. B., & Shulman, G. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00043-3 · Cited by 7
Wang, C., Yu, X., Ke, Y., Fu, Y., Luo, Y., Li, Y., Bi, Y., Chen, X., Li, L., Zhao, X., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01668-23 · Cited by 5
“Moreover, dyslipidemia is usually associated with hypertension, type 2 diabetes, and metabolic syndrome (19, 20).”
BackgroundVitamin D levels and lipid profiles in patients with polycystic ovary syndrome
Moieni, A., Haghollahi, F., Dashtkoohi, M., Abiri, A., Salari, E., Najafi, M. S., & Tajik, N. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03294-7 · Cited by 5
Diabetes and its Silent Partner: A Critical Review of Hyperinsulinemia and its Complications
Rangraze, I. R., El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Matalka, I. I., & Rizzo, M. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998311738240813110032 · Cited by 5
Metabolic Syndrome and Sasang Constitution in Cohort Study
Yun, W.-Y., Yu, J.-S., & Park, J.-K. (2013) · Journal of Sasang Constitutional Medicine · doi:10.7730/jscm.2013.25.1.1 · Cited by 5
Khan, A. A. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.16.002884 · Cited by 5
“STZ has been reported to cause a significant increase in LDL concentration which leads to DM [41,44,51].”
BackgroundTHE METABOLIC SYNDROME IN HYPERTENSION
Redon, J., Martinez, F., & Fabia, M. J. (2014) · CRC Press eBooks · doi:10.1201/b17072-46 · Cited by 5
“Atherogenic dyslipidaemia describes the combination of elevated triglycerides and low HDL cholesterol together with elevated apolipoprotein B (ApoB), small dense LDL, and small HDL particles, all of which are independently atherogenic [6], which is commonly observed in patients with both type-2 diabetes and the MS.”
BackgroundAntihyperglycemic Effects of Green Tea Extract on Alloxan-Induced Diabetic and OLETF Rats
Lee, B.-R., Koh, K.-O., & Park, P.-S. (2007) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2007.36.6.696 · Cited by 4
Life-threatening dermatoses due to metabolic and endocrine disorders
Pitambe, H. V., & Schulz, E. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.06.001 · Cited by 4
Insulin resistance and vascular disease
Maritz, F. J. (2004) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2004.11073590 · Cited by 4
Anwer, T. (2012) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp10.093 · Cited by 4
“However pharmacological interventions are needed in more severe cases of dyslipidemia and hyperglycemia (Brunzell and Ayyobi, 2002).”
BackgroundTratamiento de la dislipemia diabética con fármacos hipolipemiantes. Nuevos conceptos
Pintó, X., & Meco, J. F. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78983-4 · Cited by 4
Rizos, E. C., Tsouli, S. G., Doumas, M. N., Kostapanos, M. S., Lagos, K. G., Tselepis, A. D., & Elisaf, M. (2008) · The Open Clinical Chemistry Journal · doi:10.2174/1874241600801010064 · Cited by 3
“MetS is characterized by atherogenic dyslipidemia consisting of elevated serum triglycerides and apoB levels, increased small dense LDL particles, and reduced levels of HDL-C [1,2,15-17].”
BackgroundManagement of Hypertriglyceridemia in Uncontrolled Type 2 Diabetes Mellitus Patients: 2 Case Studies
Erişmiş, B. (2016) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2016.03.00072 · Cited by 3
Rothwell, S. W., Poth, M., McIver, H., Ayika, C., Eidelman, O., Jozwik, C., & Pollard, H. B. (2011) · Human Genomics and Proteomics · doi:10.4061/2011/323629 · Cited by 3
“SAGE-Hindawi Access to Research Human Genomics and Proteomics Volume 2011, Article ID 323629, 11 pages doi:10.4061/2011/323629”
MethodInfluentialSex differences in HDL ApoC-III in American Indian youth
Blackett, P. R., Khan, S. H., Wang, W., Alaupovic, P., & Lee, E. T. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-18 · Cited by 3
Serum Lipid Status in Patients with Polycystic Ovary Syndrome
Jahan, S., Islam, F., Ashraf, M. A., Hossain, M. Z., Khan, M. H., Ara, I., Alam, M. S., & Hoque, S. (2020) · Journal of Dhaka Medical College · doi:10.3329/jdmc.v27i2.45836 · Cited by 3
“2012, Lipid Parameters in Patients with Polycystic Ovary Syndrome, Appl Med Inform 2012;31(4):27-32.”
BackgroundYaturu, S., & Jain, S. K. (2007) · CRC Press eBooks · doi:10.1201/9781420005479.ch12 · Cited by 3
The Role of LCAT in Atherosclerosis
Ng, D. S. (2006) · Springer eBooks · doi:10.1007/0-387-36279-3_2 · Cited by 3
“HTG is a common feature in a number of highly proatherogenic conditions, namely type 2 diabetes mellitus, metabolic syndrome, and familial combined hyperlipidemia [ 49 ], in which low HDL-C, insulin resistance, central obesity are frequently present.”
BackgroundExploration of Metabolic and Endocrine Function in the Mouse
Champy, M., Argmann, C., Chambon, P., & Auwerx, J. H. (2006) · Wiley eBooks · doi:10.1002/9783527611942.ch5 · Cited by 3
Introduction and summary statements
Nesto, R. W., & Drexler, A. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.008 · Cited by 3
Treatment of lipids and type 2 diabetes
Hermayer, K. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0053-4 · Cited by 4
Metabolic syndrome in alopecia areata: an observational study at a tertiary care center
Das, S. K., & Das, S. (2021) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20213338 · Cited by 2
“Increased level of small dense lowdensity lipoprotein cholesterol (sd-LDL-C) is one of the main components of atherogenic dyslipidemia.(17) There are limited data available regarding the relationship ABSTRACT”
BackgroundRusdiana, R., Moradi, A., Widjaja, S. S., Daulay, M., & Rusmalawaty, R. (2022) · Acta Informatica Medica · doi:10.5455/aim.2022.30.201-204 · Cited by 2
“It is likely to play a leading role in the increased CVD risk associated with diabetes (11, 13, 14).”
BackgroundGlitazones: Beyond glucose lowering!
Mankovsky, B., & Kurashvili, R. B. (2007) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.06.002 · Cited by 2
Consideraciones genéticas sobre las dislipidemias y la aterosclerosis
Travieso, F., & César, J. (2008) · Revista CENIC. Ciencias biológicas · Cited by 2
Augusthy, A., Sahu, S., Jeppu, A. K., Jawalekar, S., Marakala, V., & Thattil, A. M. T. (2017) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2017.i03.23 · Cited by 2
Мамедов, М. Н. (2009) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2009-5-6-47-50 · Cited by 2
Hariri, H. M., Wahab, S. A., Johnston, M. E., Surapaneni, S., Pratt, C. G., Szu-Aun, L., Hanseman, D. J., Ahmad, S. A., Patel, S. H., & Wilson, G. C. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116482 · Cited by 1
Macrophage stimulating protein (MSP) in the metabolic syndrome
Li, ‡. (2017) · doi:10.26481/dis.20170908jl · Cited by 1
“Considering the high occurrence of T2DM and the diabetes dyslipidemia [4,5], our findings holds significant promise to its clinical application related to T2DM.”
BackgroundCraiu, E., Cojocaru, L., Rusali, A. C., Maxim, R., & Parep, I. (2012) · InTech eBooks · doi:10.5772/31143 · Cited by 1
Мамедов, М. Н. (2009) · Рациональная фармакотерапия в кардиологии
Polycystic Ovary Syndrome and Cardiovascular Disease
nder, B., Taner, D., Ylmaz, H., & Muzaffer, M. (2012) · InTech eBooks · doi:10.5772/25519
“As a result, raised hepatic delivery of free fatty acids impairs insulin inhibition of hepatic very low-density lipoprotein 1 synthesis, causing altered catabolism of very low-density lipoprotein (Brunzell and Ayyobi 2003).”
BackgroundEL SÍNDROME METABÓLICO EN LA CLÍNICA ACTUAL
Bruce, A. A., & Carraté, J. A. (2007) · Revista Archivo Médico de Camagüey
Espinoza, M., Figueira, D., Cid, S., Barrios, E., Ruiz, N., Leal, U., & Coccione, S. (2012) · Redalyc (Universidad Autónoma del Estado de México)
Trautmann, A., Bröcker, E., & Seitz, C. S. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.013
Barrientos‐Alvarado, C., Vázquez, J. S., Oscoy, M. A. S. C., Garrido-Acosta, O., & Anguiano‐Robledo, L. (2014) · Revista de Nutrição · doi:10.1590/1415-52732014000600004
Acute, ambulatory and central blood pressure measurements in diabetes
Wijkman, M. O. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Fiber Treating Metabolic Syndrome
Stamatikos, W. J. B. A. D. (2013) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000130
“High triglycerides and apolipoprotein B along with low levels of high density lipoproteins are known to be atherogenic [51] and their respective concentrations are used to determine atherogenic dyslipidemia [15].”
BackgroundTreatment with Thiazolidinediones
Suvag, S., Utzschneider, K. M., & Kahn, S. E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_9
Kim, Y. (2005)
Sex differences in HDL ApoC-III in American
Blackett, P. R., Khan, S. H., Wang, W., Alaupovic, P., & Lee, E. T. (2012)
A COMPENDIOUS REVIEW ON THE METABOLIC SYNDROME; ITS IMPACT ON THE QUALITY OF LIFE
Rajalakshimi, V., & Aanandhi, M. V. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11s4.31687
Rojas, J., Chávez-Castillo, M., Olivar, L. C., & Bermúdez, V. (2013) · Redalyc (Universidad Autónoma del Estado de México)
Oberfield, S. E., Leibel, N. I., Antler, L., Silfen, M. E., Levine, L. S., Horlick, M., Carbunaru, G., López, X., & Pang, S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_12
Das, S., Zahan, K. F. I., Rashid, M. M., Sarkar, A. C., Khan, S. I., Ashfaq, M., Mahbub, H. M., Islam, R., Khan, S. I., & Kabir, S. H. (2020) · Journal of Dhaka Medical College · doi:10.3329/jdmc.v27i2.45835
(2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137218.37245.2e
Physical activity, exercise, and the metabolic syndrome
Haapala, E. A., & Leppänen, M. H. (2023) · doi:10.1093/med/9780192843968.003.0020
Cardiometabolic profile of some staff of Police Academy (POLAC), Wudil, Kano State, Nigeria
Nwachukwu, F. C. (2025) · Journal of Pharmacy and Allied Medicine · doi:10.58985/jpam.2025.v03i02.38
Joshi, G., Goutam, N., Shivani, S., Kaushal, K. P., Sharma, A., Harmanbir, K., & Joshi, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-60346
El-Gammal, H., Ebeed, N., El-bakry, K. A.-E. K. M., & Hyder, A. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00830-2
“Obesity, metabolic syndrome (MetS) and type 2 diabetes (T2D) are characterized by dyslipidemia, which includes hypertriglyceridemia, raised levels of blood apo-lipoprotein B and low-density lipoprotein (LDL cholesterol), and decreased levels of high-density lipoprotein (HDL cholesterol) [13, 14].”
Beason, T. S. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Brunzell, J. D., & Ayyobi, A. F.
- Affiliations
- University of Washington (US)
- Corresponding author
- Ayyobi, Amir F
- ORCID
- Brunzell, John D
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 115
- Issue
- 8
- Pages
- 24-28
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2030751874
- Cited by
- 155
- References
- 63
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 12 · 2013: 10 · 2012: 12
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia, metabolic syndrome, type 2 diabetes, hypertriglyceridemia, apolipoprotein B, small dense LDL, HDL cholesterol, HDL2-C, lipoprotein heterogeneity, statins, fibrates, thiazolidinediones, nicotinic acid, coronary heart disease prevention
- MeSH terms
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Lipase, Cholesterol, HDL, Cholesterol, LDL, Receptor, Insulin, Risk Factors, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
